Lucía Pérez-Lamas, Raquel de Paz Arias, Rosa Mª Ayala Díaz, Luis Felipe Casado Montero, Ángel Ramírez Payer, Magdalena Sierra, Francisca Ferrer Marín, Raúl Pérez López, Blanca Xicoy Cirici, Juan Luis Steegmann, María Teresa Gómez Casares, Joaquín Martínez-López, Valentín García-Gutiérrez
In the field of chronic myeloid leukemia (CML), new strategies are needed to increase the rate of successful treatment discontinuations, a crucial goal in this disease. Anti-PD-L1 checkpoint inhibitors are a promising therapeutic approach in CML after the demonstration of an increase of these inhibitory molecules in patients with CML. A phase Ib/II (NCT04793399, registration date March 11, 2021) open-label exploratory trial has been conducted to evaluate the safety of atezolizumab, a humanized anti-PD-L1 antibody, in combination with bosutinib in patients with newly diagnosed chronic phase CML...
April 3, 2024: Annals of Hematology